K2M Group Holdings Inc. (NASDAQ:KTWO) shares traded down 1.6% during mid-day trading on Thursday . The company traded as low as $16.73 and last traded at $16.79, with a volume of 322,833 shares trading hands. The stock had previously closed at $17.06.

A number of research analysts recently issued reports on the stock. Piper Jaffray Cos. reiterated a “buy” rating on shares of K2M Group Holdings in a research report on Saturday, April 2nd. Needham & Company LLC reiterated a “buy” rating and set a $21.00 target price on shares of K2M Group Holdings in a research report on Tuesday, May 3rd. Northland Securities downgraded shares of K2M Group Holdings from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 3rd. JMP Securities reiterated a “buy” rating and set a $22.00 target price on shares of K2M Group Holdings in a research report on Sunday, June 5th. Finally, Zacks Investment Research downgraded shares of K2M Group Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.67.

The company’s 50 day moving average price is $15.04 and its 200 day moving average price is $14.25. The firm’s market capitalization is $704.83 million.

K2M Group Holdings (NASDAQ:KTWO) last issued its quarterly earnings results on Monday, May 2nd. The medical device company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.02. The business had revenue of $56.20 million for the quarter, compared to analyst estimates of $56 million. K2M Group Holdings’s revenue was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.37) EPS. Equities research analysts forecast that K2M Group Holdings Inc. will post ($1.10) earnings per share for the current fiscal year.

In other news, Director Carlos A. Ferrer bought 20,000 shares of the business’s stock in a transaction dated Thursday, May 5th. The shares were purchased at an average price of $11.32 per share, for a total transaction of $226,400.00. Following the completion of the acquisition, the director now owns 59,382 shares of the company’s stock, valued at $672,204.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Gregory S. Cole sold 6,465 shares of the firm’s stock in a transaction that occurred on Saturday, May 21st. The stock was sold at an average price of $11.32, for a total transaction of $73,183.80. Following the completion of the transaction, the chief financial officer now owns 33,233 shares in the company, valued at approximately $376,197.56. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have recently modified their holdings of the company. Paradigm Capital Management Inc. NY boosted its position in shares of K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock valued at $3,350,000 after buying an additional 146,300 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of K2M Group Holdings by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 398,277 shares of the medical device company’s stock valued at $7,862,000 after buying an additional 5,127 shares in the last quarter. OppenheimerFunds Inc. boosted its position in shares of K2M Group Holdings by 13.1% in the fourth quarter. OppenheimerFunds Inc. now owns 908,054 shares of the medical device company’s stock valued at $17,925,000 after buying an additional 105,014 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of K2M Group Holdings by 1.6% in the fourth quarter. New York State Common Retirement Fund now owns 141,690 shares of the medical device company’s stock valued at $2,797,000 after buying an additional 2,170 shares in the last quarter. Finally, Columbus Circle Investors boosted its position in shares of K2M Group Holdings by 20.4% in the fourth quarter. Columbus Circle Investors now owns 510,062 shares of the medical device company’s stock valued at $10,069,000 after buying an additional 86,497 shares in the last quarter.

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.